Andere talen Bavarian Nordic A/S OTC Markets

Aandelen

BVNRY

US0717711099

Beurs gesloten - OTC Markets Andere beurzen 21:56:03 31-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
8,93 ^USD	+4,66%		+3,18%	+2,12%

31/05	Bavarian Nordic dient aanvullende Amerikaanse licentieaanvraag in voor pokken- en apenpokkenvaccin	MT
30/05	Bavarian Nordic krijgt $6,5 miljoen financiering voor de ontwikkeling van een Mpox-vaccin voor kinderen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine	31/05
Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children	30/05
Bavarian Nordic’s Medical Chief to Step Down by May-end	21/05
Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer	21/05
Transcript : Bavarian Nordic A/S, Q1 2024 Earnings Call, May 08, 2024	08/05
Bavarian Nordic A/S commences an Equity Buyback Plan, under the authorization approved on April 16, 2024.	08/05
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024	08/05
Bavarian Nordic A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Bavarian Nordic Books EUR65 Million Order for Smallpox Vaccine	30/04
Bavarian Nordic A/S Receives EUR 65 Million Contract to Supply Smallpox Vaccines for EU Strategic Reserve	29/04
Bavarian Nordic Starts US Rolling Submission Process for Chikungunya Vaccine Candidate	29/04
Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate	29/04
Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults	13/03
Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland	13/03
Transcript : Bavarian Nordic A/S, 2023 Earnings Call, Mar 06, 2024	06/03
Bavarian Nordic A/S Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Bavarian Nordic A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03
Transcript : Bavarian Nordic A/S - Analyst/Investor Day	27/02
Bavarian Nordic Receives Accelerated Assessment Status for Chikungunya Vaccine	23/02
Bavarian Nordic A/S Announces Accelerated Assessment for the Upcoming Marketing Authorisation Application for CHIKV VLP	23/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Bavarian Nordic A/S OTC Markets

Aandelen

BVNRY

US0717711099

Andere talen

Filters